27.19
29.46 (01.08%)
As of Mar 06, 2024
PFIZER INC [PFE]
As of Feb 22, 2024 | Source: Annual Report to the SEC
Company Overview
Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
| Country | United States |
| Headquarters | New York, New York |
| Phone Number | 2127332323 |
| Industry | Chemicals And Allied Products |
| Employees | 88000 |
| CEO | Albert Bourla |
| Website | www.pfizer.com |
PFIZER INC [PFE] As of Aug 10, 2022| Source: Quarterly Report to the SEC Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies...
PFIZER INC [PFE] As of Aug 09, 2013| Source: Quarterly Report to the SEC Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies...
PFIZER INC [PFE] As of May 11, 2022| Source: Quarterly Report to the SEC Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies...
Picture credit: Bloomberg Pfizer Inc. (NYSE: PFE) today announced that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer a...
Pfizer Inc. [PFE] reported financial results for second-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) driven by its updated expectations for contributions to 2021 p...
Financial Overview
| Revenue | 58,496 M |
| Profits | 2,158 M |
| Net Cash | 2,448 M |
Management Effectiveness
| Return on Equity | -1.25% |
| Return on Assets | -0.49% |
| Turnover Ratio | 0.28 M |
Profit Ratios
| Gross Margin | 33,542 M |
| Profit as % of Revenues | 1554.31% |
| Profit as % of Assets | 1.02% |
| Profit as % of Stockholder Equity | 2.42% |
Balance Sheet and Cash Flow Measures
| Total Assets | 226,501 M |
| Total Liabilities | 137,213 M |
| Operating Cash Flow | 8,700 M |
| Investing Cash Flow | -32,278 M |
| Financing Cash Flow | 26,066 M |